Specialties – Page 159

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

By MedXY 10/28/2025

Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.

Gastroenterology news Oncology

Unveiling the Molecular Link Between Alcohol and HBV-Driven Liver Cancer: The Role of ATF4/LPLA2-Mediated BMP Metabolism

By MedXY 10/28/2025

Chronic alcohol intake exacerbates HBV-induced hepatocellular carcinoma by activating the ATF4/LPLA2 pathway, promoting BMP metabolism and MAPK/ERK signaling, identifying LPLA2 as a potential therapeutic target and prognostic marker.

news Oncology

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY 10/28/2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

news Oncology

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY 10/28/2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making.

Allergy & Immunology Dermatology news

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

By MedXY 10/28/2025

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

news Respiratory Rheumatology

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

By MedXY 10/28/2025

This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.

Gastroenterology Internal Medicine news

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY 10/28/2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted therapy as a novel approach.

news Oncology

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY 10/28/2025

A recent phase II trial demonstrates lenvatinib's efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Critical Care Gastroenterology news

Innovative Extracorporeal Therapy Combining HLA-Depleted Liver Organoids and Granulocyte-Monocyte Apheresis for Reversal of Acute Liver Failure

By MedXY 10/28/2025

The UTOpiA system, integrating HLA-depleted iPSC-derived liver organoids with granulocyte-monocyte apheresis, significantly improves survival and liver regeneration in acute-on-chronic and acute liver failure rat models, representing a promising off-the-shelf extracorporeal liver support therapy.

Gastroenterology Internal Medicine news

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

By MedXY 10/28/2025

This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in biochemical responders.

Gastroenterology news Pathology & Lab Medicine

Liver Stiffness Measurement vs. Biochemical Response in Primary Biliary Cholangitis: Predicting Liver Decompensation with Precision

By MedXY 10/28/2025

In primary biliary cholangitis, liver stiffness measurement (LSM) outperforms biochemical response in predicting first hepatic decompensation, emphasizing LSM's pivotal role in clinical risk stratification despite frequent discordances between these parameters.

Gastroenterology news Pathology & Lab Medicine

Standardizing Liver Biopsy Interpretation in MASH Trials: Key Consensus Statements from the International MASLD Pathology Group

By MedXY 10/28/2025

An evidence-based, practical summary of the IMPG consensus on standardized histologic grading and staging for MASH (MASLD) clinical trials, with recommendations for biopsy processing, feature definitions, scoring, central reading, and AI-ready datasets.

Nephrology news Transplantation

IXA Position Paper: Practical Roadmap for First-in-Human Porcine Kidney Xenotransplantation

By MedXY 10/28/2025

The International Xenotransplantation Association (IXA) 2025 position paper offers evidence-based recommendations for initial clinical trials of genetically engineered porcine kidney transplants for end-stage renal disease, focusing on donor genetics, immunosuppression, patient selection, infection monitoring and ethical/regulatory safeguards.

Gastroenterology General Surgery news

Breaking New Ground: The First Genetically Engineered Pig-to-Human Liver Xenotransplantation

By MedXY 10/28/2025

This landmark study reports the first successful genetically engineered pig auxiliary liver transplanted into a living human, revealing critical insights on immunological compatibility and post-transplant complications, advancing liver xenotransplantation toward clinical application.

news Oncology

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY 10/27/2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

Cardiology Gastroenterology news

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality

By MedXY 10/27/2025

Early-stage portopulmonary hypertension, defined by revised 2022 ESC/ERS criteria, independently predicts mortality in patients with cirrhosis, underscoring the importance of systematic screening and early intervention.

Infectious Diseases Internal Medicine news

Targeting HBx-Induced HSPB1: A Novel Approach to Combat Chronic Hepatitis B and Boost Liver Immunity

By MedXY 10/27/2025

This review explores the potential of targeting HBx-induced HSPB1 to suppress HBV cccDNA and enhance hepatic immune responses, highlighting a promising peptide-based therapeutic approach.

Internal Medicine Neurology news

Emerging Role of GLP-1 and GIP/GLP-1 Receptor Agonists in Managing Idiopathic Intracranial Hypertension

By MedXY 10/27/2025

This review analyzes current evidence supporting the use of GLP-1 and GIP/GLP-1 receptor agonists in IIH, highlighting benefits in reducing papilledema, visual disturbances, and headaches.

Clinical Updates Neurology news

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: Emerging Evidence and Clinical Implications

By MedXY 10/27/2025

GLP-1 receptor agonists show promise in idiopathic intracranial hypertension by reducing symptoms, medication use, surgical interventions, and mortality, independent of significant BMI change, highlighting a novel therapeutic approach warranting further prospective evaluation.